Aqueous composition
By incorporating dibutylhydroxytoluene and adjusting the pH to 6.5 or less, the thermal stability of ketotifen and pranoprofen in aqueous compositions is improved, ensuring effective and stable formulations for treatments.
Patent Information
- Application Number
- JP2024161648
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2009-06-16
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-28
AI Technical Summary
Aqueous compositions containing ketotifen and pranoprofen suffer from insufficient thermal stability, leading to yellowing and reduced efficacy due to destabilization of ketotifen salts, which affects their effectiveness in treatments.
Incorporating dibutylhydroxytoluene as an antioxidant and adjusting the pH of the composition to 6.5 or less, along with optional components like surfactants, polyhydric alcohols, and borate buffers, to stabilize ketotifen and pranoprofen.
The method significantly enhances the thermal stability of ketotifen and pranoprofen, maintaining the composition's appearance and effectiveness, particularly in ophthalmic applications like eye drops, by preventing yellowing and maintaining active ingredient content.
Smart Images

Figure 2024166380000006 
Figure 2024166380000007 
Figure 2024166380000008
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical composition comprising ketotifen and / or a salt thereof and pranoprofen and / or a salt thereof. The present invention relates to an aqueous composition having improved thermal stability of ketotifen and / or its salts, Furthermore, the present invention relates to a combination of ketotifen and / or a salt thereof and pranoprofen and / or a salt thereof. Method for improving the thermal stability of ketotifen and / or its salt in an aqueous composition comprising the compound and a salt thereof Regarding the law. [Background technology]
[0002] Ketotifen and / or its salts act as chemical mediators in addition to their antihistamine effects. It has pharmacological effects such as inhibiting the release of eosinophils and the activation of eosinophils, and is used as an anti-allergic agent. It is widely used as an eye drop, nasal drop, and oral medication.
[0003] In addition, pranoprofen and / or its salts have excellent anti-inflammatory, analgesic and antipyretic effects. It is known as a nonsteroidal anti-inflammatory agent of the propionic acid family that has both properties and is highly safe. For this reason, it is widely used as an eye drop or oral preparation.
[0004] And, up to now, water containing ketotifen fumarate and pranoprofen at the same time has been Sexual compositions are known (see Patent Documents 1 to 4).
[0005] For example, Patent Document 1 discloses a method for dissolving pranoprofen at a pH of 6.8 or higher, and then After adding ketotifen fumarate, the pH was adjusted to 5 to 6.5. Pranoprofen and ketotifen fumarate that can be maintained stable over time without causing sludge or cloudiness It is described that an eye drop containing the above can be obtained.
[0006] Patent Document 2 describes a product that is highly effective in reducing eye fatigue and has improved stability against light. A composition containing pranoprofen or a salt thereof and neostigmine methylsulfate is disclosed. Patent Document 2 also describes pranoprofen and neostigmine methylsulfate. In addition, it contains ketotifen fumarate and dibutylhydroxytoluene, and has a pH of 7.0. An eye drop comprising the compound is described.
[0007] Patent Document 3 also describes a material that has a high effect of improving eye fatigue and has improved stability against light. Also disclosed is a composition containing pranoprofen or a salt thereof and a glycyrrhizinate salt. Patent Document 3 also describes a combination of pranoprofen and dipotassium glycyrrhizinate. In addition, it contains ketotifen fumarate and dibutylhydroxytoluene, and has a pH of 7.0. An eye drop formulation is described.
[0008] Patent Document 4 also describes a compound that is inhibited from being decomposed by light, such as (A) pranoprofen or a salt thereof, An aqueous composition is disclosed that contains (B) a zinc compound, and (C) citric acid or a salt thereof. In addition, Patent Document 4 describes a compound containing pranoprofen, zinc sulfate, and sodium citrate. , containing ketotifen fumarate and dibutylhydroxytoluene, and having a pH of 7.0. Eye drops are described.
[0009] On the other hand, the aqueous solution of pranoprofen was mixed with an antioxidant such as dibutylhydroxytoluene. A method for stabilizing pranoprofen (particularly against light), comprising the step of: However, Patent Document 5 also describes the use of an antioxidant in combination. Although stabilization of pranoprofen by There is no description of the relationship between stabilization and pH, much less the thermal stabilization of ketotifen fumarate. There is no instruction on techniques for improving quality. [Prior art documents] [Patent documents]
[0010] [Patent Document 1] JP 2005-272462 A [Patent Document 2] JP 2006-232822 A [Patent Document 3] JP 2006-232823 A [Patent Document 4] JP 2006-249076 A [Patent Document 5] Japanese Patent Application Publication No. 7-304670 Summary of the Invention [Problem to be solved by the invention]
[0011] The present inventors have discovered that ketotifen and / or a salt thereof and pranoprofen and / or a salt thereof As a result of various investigations into aqueous compositions containing ketotifen and / or When pranoprofen and / or its salt are combined with the salt, keto The thermal stability of thifen and / or its salt becomes insufficient, causing the composition itself to turn yellow. Thus, we have obtained a completely new finding that the thermal stability of ketotifen and / or its salts is improved. Insufficient stability and yellowing due to destabilization of ketotifen and / or its salts. This not only impairs the appearance but also reduces the content of ketotifen and / or its salts in the composition. This may result in a decrease in the efficacy of the aqueous composition when used for treatment or the like. Therefore, ketotifen and / or its salts and pranoprofen and / or its salts may be The thermal stability of ketotifen and / or its salts is improved while containing a salt thereof, and the formulation There is a need to develop techniques for obtaining aqueous compositions that are excellent in terms of the properties. [Means for solving the problem]
[0012] As a result of intensive research to solve the above problems, the present inventors have found that ketotifen and / or The aqueous composition containing the salt and pranoprofen and / or a salt thereof further contains dibutyl ether. By blending hydroxytoluene and adjusting the pH of the composition to 6.5 or less, Ketotifen and / or its salts which are unstable when coexisting with noprofen and / or its salts It has been found that the thermal stability of the salt can be significantly improved. Based on this, and through further consideration, it was completed.
[0013] That is, the present invention provides an aqueous composition having the following aspects. Item 1-1. (A) at least one selected from the group consisting of ketotifen and its salts, and (B) (C) at least one selected from the group consisting of pranoprofen and its salts, An aqueous composition comprising hydroxytoluene and having a pH of 6.5 or less. Composition. Item 1-2. The aqueous composition according to Item 1-1, comprising ketotifen fumarate as component (A). Item 1-3. The aqueous composition according to Item 1-1 or 1-2, comprising pranoprofen as component (B). Item 1-4. The aqueous composition according to any one of Items 1-1 to 1-3, further comprising a surfactant (D). Item 1-5. The aqueous composition according to Item 1-4, further comprising a nonionic surfactant as component (D). Item 1-6. The aqueous composition according to any one of Items 1-1 to 1-5, further comprising (E) a polyhydric alcohol. thing. Item 1-7. The aqueous composition according to item 1-6, comprising glycerin as component (E). Item 1-8. The aqueous composition according to any one of Items 1-1 to 1-7, further comprising (F) a borate buffer. . Item 1-9. The water-soluble polymer composition according to Item 1-8, which contains boric acid and an alkali metal salt of boric acid as the component (F). sexual composition. Item 1-10. The aqueous composition according to Item 1-8 or 1-9, comprising boric acid and borax as the component (F). . Item 1-11. Any one of Items 1-8 to 1-10, wherein the pH is adjusted to 6.5 or less with a borate buffer. The aqueous composition described above. Item 1-12. The aqueous composition according to any one of Items 1-1 to 1-11, which is an ophthalmic composition. Item 1-13. The aqueous composition according to any one of Items 1-1 to 1-12, which is an eye drop.
[0014] The present invention also relates to ketotifen and / or a salt thereof in an aqueous composition, as described below. The present invention provides a method for improving the thermal stability of Item 2-1. The aqueous composition comprises (A) at least one selected from the group consisting of ketotifen and its salts. (B) at least one selected from the group consisting of pranoprofen and its salts. Both of them contain (C) dibutylhydroxytoluene and have a pH of 6.5 or more. The present invention relates to a method for producing a thermally stable composition comprising the steps of: How to improve stability against Item 2-2. The method for improving stability according to Item 2-1, comprising the step of containing ketotifen fumarate as component (A). . Item 2-3. The method for improving stability according to Item 2-1 or 2-2, comprising the step of containing pranoprofen as the component (B). Law. Item 2-4. The method for improving stability according to any one of Items 2-1 to 2-3, further comprising blending a surfactant (D). Law. Item 2-5. The method for improving stability according to Item 2-4, further comprising the step of containing a nonionic surfactant as the component (D). . Item 2-6. The stability-improving composition according to any one of Items 2-1 to 2-5, further comprising (E) a polyhydric alcohol. Good method. Item 2-7. The method for improving stability according to Item 2-6, further comprising containing glycerin as the component (E). Item 2-8. The method for improving stability according to any one of Items 2-1 to 2-7, further comprising blending (F) a borate buffer. method. Item 2-9. The stabilizer according to Item 2-8, which contains boric acid and an alkali metal salt of boric acid as the component (F). Qualitative improvement method. Item 2-10. (F) Contains boric acid and borax as ingredients. The method for improving stability according to Item 2-8 or 2-9. Item 2-11. Any of items 2-8 to 2-10, in which the pH is adjusted to 6.5 or less using a borate buffer. The method for improving stability described above. Item 2-12. The stability method according to any one of Items 2-1 to 2-11, wherein the aqueous composition is an ophthalmic composition. How to improve. Item 2-13. The method for improving stability according to any one of Items 2-1 to 2-12, wherein the aqueous composition is an eye drop. Law.
[0015] Furthermore, the present invention relates to a thermal stability improver for ketotifen and / or a salt thereof, to provide. Item 3-1. (A) at least one selected from the group consisting of ketotifen and its salts, and (B) At least one member selected from the group consisting of pranoprofen and a salt thereof in an aqueous composition. It is an agent for improving the thermal stability of the (A) component when the (A) component is used in the presence of the (A) component. (C) dibutylhydroxytoluene is contained, and the final pH of the aqueous composition is 6. A thermal stability improver characterized by comprising an aqueous base adjusted to have a viscosity of .5 or less. Item 3-2. The heat stability improver according to Item 3-1, containing ketotifen fumarate as component (A). . Item 3-3. The composition for improving thermal stability according to Item 3-1 or 3-2, which contains pranoprofen as the component (B). Agent. Item 3-4. The thermal decomposition composition according to any one of Items 3-1 to 3-3, wherein the aqueous base further contains a surfactant (D). Stability improver. Item 3-5. The heat stability improver according to Item 3-4, which contains a nonionic surfactant as the component (D). . Item 3-6. The aqueous base further contains (E) a polyhydric alcohol, as described in any one of Items 3-1 to 3-5. Heat stability improver. Item 3-7. The heat stability improver according to Item 3-6, comprising glycerin as the (E) component. Item 3-8. The method according to any one of Items 3-1 to 3-7, wherein the aqueous base further contains (F) a borate buffer. Thermal stability improver. Item 3-9. The heat-resistant composition according to Item 3-8, which contains boric acid and an alkali metal salt of boric acid as the component (F). Stability improver. Item 3-10. The heat stability improving agent according to item 3-8 or 3-9, containing boric acid and borax as the component (F). Good medicine. Item 3-11. The final pH of the solution is adjusted to 6.5 or less with a borate buffer. 8. A thermal stability improver according to any one of claims 3 to 10. Item 3-12. The heat-stable aqueous composition according to any one of Items 3-1 to 3-11, wherein the aqueous composition is an ophthalmic composition. Sexual improver. Item 3-13. The method for improving thermal stability according to any one of Items 3-1 to 3-12, wherein the aqueous composition is an eye drop. Agent.
[0016] Furthermore, the present invention provides the following uses. Item 4-1. (A) at least one selected from the group consisting of ketotifen and its salts, and (B) and at least one selected from the group consisting of pranoprofen and a salt thereof, (C) dibutyl hydroxypropyl ether to produce an aqueous composition having improved thermal stability of the components The aqueous composition contains hydroxytoluene and is adjusted so that the final pH of the aqueous composition is 6.5 or less. Use of a balanced aqueous base. Item 4-2. The use according to Item 4-1, comprising ketotifen fumarate as the component (A). Item 4-3. The use according to Item 4-1 or 4-2, comprising pranoprofen as the component (B). Item 4-4. The composition according to any one of Items 4-1 to 4-3, wherein the aqueous base further contains a surfactant (D). use. Item 4-5. The use according to Item 4-4, comprising a nonionic surfactant as component (D). Item 4-6. The composition according to any one of Items 4-1 to 4-5, wherein the aqueous base further contains (E) a polyhydric alcohol. Use of the above. Item 4-7. The use according to Item 4-6, further comprising glycerin as the (E) component. Item 4-8. The aqueous base according to any one of Items 4-1 to 4-7, further comprising (F) a borate buffer. Use of. Item 4-9. The use according to Item 4-8, which contains boric acid and an alkali metal salt of boric acid as the component (F). For. Item 4-10. The use according to item 4-8 or 4-9, comprising boric acid and borax as the (F) component. Item 4-11. The aqueous base is adjusted with borate buffer to a final pH of 6.5 or less. The use according to any one of Items 4-8 to 4-10. Item 4-12. The use according to any one of Items 4-1 to 4-11, wherein the aqueous composition is an ophthalmic composition. . Item 4-13. The use according to any one of Items 4-1 to 4-12, wherein the aqueous composition is an eye drop. Effect of the Invention
[0017] According to the present invention, ketotifen and / or its salts are combined with pranoprofen and / or The thermal stability of ketotifen and / or its salts is improved while containing the salts. In addition, it is possible to provide an aqueous composition which is excellent in formulation. [Brief description of the drawings]
[0018] [Figure 1] FIG. 2 is a graph showing the results of evaluating the thermal stability of ketotifen fumarate in test solutions 1, 2, and 4 in Test Example 1. [Diagram 2] FIG. 2 is a graph showing the results of evaluating the thermal stability of ketotifen fumarate in test solutions 5-7 in Test Example 2. [Diagram 3] FIG. 2 is a graph showing the results of evaluating the thermal stability of ketotifen fumarate in test solutions 8-10 in Test Example 3. [Figure 4] FIG. 1 shows the results of evaluating the thermal stability of ketotifen fumarate in test solutions 11-16 in Test Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] 1.Aqueous composition The aqueous composition of the present invention comprises at least one compound selected from the group consisting of ketotifen and its salts. Contains one type (hereinafter sometimes simply referred to as component (A)).
[0020] Ketotifen is a 4,9-dihydro-4-(1-methyl-4-piperidylidene)-10 Also called H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one Ketotifen and its salts are compounds known as antiallergic agents. They can be synthesized by known methods or are commercially available.
[0021] Among the above-mentioned components (A) used in the present invention, the salt of ketotifen has medicinal and pharmacological properties. There are no particular limitations as long as it is pharma- ceutical or physiologically acceptable. , organic acid salts [e.g., monocarboxylates (acetates, trifluoroacetates, butyrates, palmitates, salts (tin salts, stearates, etc.), polycarboxylates (fumarates, maleates, amber salts salts (lactates, tartrates, citrates, etc.), organic Sulfonates (methanesulfonates, toluenesulfonates, tosylates, etc.), inorganic Acid salts (e.g., hydrochlorides, sulfates, nitrates, hydrobromides, phosphates, etc.), salts with organic bases (e.g., methylamine, triethylamine, triethanolamine, morpholine, pipette salts with organic amines such as aldehyde, pyrrolidine, tripyridine, picoline, etc.) and salts with inorganic bases Salts [e.g., ammonium salts; alkali metal (sodium, potassium, etc.), alkaline earth Metals (calcium, magnesium, etc.), salts with metals such as aluminum, etc. Among these salts, organic acid salts and / or inorganic acid salts are preferred, and organic acid salts are more preferred. salts, more preferably polycarboxylates, even more preferably fumarates and / or maleates The phosphate salts are particularly preferably the fumarate salts. These salts of ketotifen may be used singly. They may be used alone or in any combination of two or more.
[0022] The aqueous composition of the present invention contains, as component (A), one of ketotifen and its salts. You can use one of them alone or two or more of them in any combination. The component (A) used in the present invention is preferably a salt of ketotifen, more preferably Ketotifen is an organic acid salt and / or an inorganic acid salt, more preferably an organic acid salt of ketotifen. More preferably, the polycarboxylic acid salt of ketotifen, and even more preferably, the polycarboxylic acid salt of ketotifen Fumarate and / or maleate, particularly preferably the fumarate of ketotifen (fumar Ketotifen (acetate).
[0023] In the aqueous composition of the present invention, the blending ratio of the above-mentioned component (A) depends on the type of the component (A) and the blending ratio of other components. The amount is appropriately set depending on the type of component, etc., but as an example, the amount of the aqueous composition is The total amount of component (A) is 0.01 to 1 w / v%, preferably 0.03 to 0.5 w / v%, and more preferably The concentration is, for example, 0.03 to 0.1 w / v %, and particularly preferably 0.05 to 0.1 w / v %.
[0024] The aqueous composition of the present invention further comprises a compound selected from the group consisting of pranoprofen and its salts. Contains at least one type (hereinafter sometimes simply referred to as component (B)).
[0025] Pranoprofen is an α-methyl-5H-[1]benzopyrano[2,3-b]pyridine-7 -acetic acid is a known compound, which may be synthesized by known methods or is commercially available. You can also do it by hand.
[0026] Among the above-mentioned components (B) used in the present invention, the salt of pranoprofen has medicinal and pharmacological properties. There are no particular limitations as long as it is clinically (pharmaceutical) or physiologically acceptable. salts with inorganic bases [e.g., sodium salts, potassium salts, calcium salts, magnesium salts, etc.] salts, aluminum salts, etc.] and salts with organic bases [e.g., methylamine, triethylamine , diethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, tri Salts with pyridine, picoline, etc. These salts of pranoprofen include one type. They may be used alone or in any combination of two or more.
[0027] The aqueous composition of the present invention contains, as component (B), one selected from pranoprofen and its salts. You can use one of each of these alone or two or more of these in any combination. As the component (B) used in the present invention, pranoprofen is preferably used. do.
[0028] In the aqueous composition of the present invention, the blending ratio of the above-mentioned component (B) depends on the type of the component (B) and the blending ratio of other components. The amount of the component (B) is appropriately determined depending on the type of the component, for example, based on the total amount of the aqueous composition. The total amount of the components is 0.01 to 1.5 w / v%, preferably 0.03 to 0.5 w / v%, and more preferably Examples of the concentration are 0.04 to 0.1 w / v%.
[0029] In the aqueous composition of the present invention, the ratio of the component (B) to the component (A) is particularly Although not limited thereto, as an example, the above may be used per 100 parts by weight of the total amount of the (A) component. The total amount of the component (B) is 2 to 1000 parts by weight, preferably 10 to 400 parts by weight, and more preferably is 50 to 200 parts by weight, more preferably 50 to 150 parts by weight, and particularly preferably 50 to 10 The range of 0 parts by weight is exemplified.
[0030] Furthermore, the aqueous composition of the present invention contains, in addition to the above components (A) and (B), dibutylhydroxytoluene. Contains dibutyl hydroxytoluene (hereinafter, simply referred to as component (C)). Ene, also known as 2,6-bis(1,1-dimethylethyl)-4-methylphenol, is an antioxidant. It is a known compound.
[0031] In the aqueous composition of the present invention, the blending ratio of the above-mentioned component (C) depends on the types of other blended components, etc. The amount of the component (C) is appropriately set depending on the amount of the aqueous composition. For example, the amount of the component (C) is 0.000 1 to 0.02 w / v%, preferably 0.0005 to 0.01 w / v%, more preferably 0.00 Examples include 1 to 0.005 w / v%.
[0032] In the aqueous composition of the present invention, the ratio of the component (C) to the component (A) is particularly Although not limited thereto, as an example, the above may be used per 100 parts by weight of the total amount of the (A) component. The amount of the component (C) is 0.1 to 40 parts by weight, preferably 0.5 to 20 parts by weight, and more preferably 1 to 20 parts by weight. An example of the range is 15 parts by weight, and more preferably 1 to 10 parts by weight.
[0033] The aqueous composition of the present invention contains the above components (A) to (C) and has a pH of 6.5 or less. In this way, by allowing the above components (A) to (C) to coexist under specific pH conditions, This suppresses the thermal destabilization of component (A) caused by component (B), thereby improving stability. It becomes possible to provide an excellent aqueous composition.
[0034] From the viewpoint of effectively imparting thermal stability to component (A) even in the presence of component (B), The pH of the aqueous composition of the present invention is preferably 6.2 or less. The lower limit of the pH of the composition shall be the limit that is medicamentally, pharmacologically (pharmaceutical) or physiologically acceptable. As long as it is within the range, it is not particularly limited, but for example, it is 4.0 or more, preferably 5.0 or more, More preferably, it is 5.5 or more, and even more preferably, it is 5.8 or more.
[0035] The pH can be adjusted using a buffer, a pH adjuster, an isotonicity agent, a salt, or the like that is commonly used in the art. This can be done by methods known in the art using, for example, an acidifier or a tertiary amine. Preferably, the pH is adjusted. is carried out using buffers and / or pH adjusters commonly used in the art. .
[0036] The aqueous composition of the present invention preferably further contains a surfactant. The surfactants that can be incorporated in the composition include those that are medicamentally, pharmacologically (pharmaceutical) or physiologically acceptable. There are no particular limitations on the surfactants, but they may be nonionic surfactants, amphoteric surfactants, anionic surfactants, etc. The surfactant may be either an anionic surfactant or a cationic surfactant.
[0037] Specific examples of nonionic surfactants that can be incorporated in the aqueous composition of the present invention include monocyclic and / or dicyclic surfactants. Polysorbate 20, POE(20) sorbitan monopalmitate (Polysorbate 40), POE (20) monostearate, sorbitan (Polysorbate 60) , POE(20) tristearate, sorbitan (polysorbate 65), POE(20) monooleate POE sorbitan fatty acid esters such as sorbitan (polysorbate 80); poloxamer 407; Poloxamer 235, Poloxamer 188, Poloxamer 403, Poloxamer 237, Poloxamer POE·POP block copolymers such as 124; POE(60) hydrogenated castor oil (polyoxyethylene hydrogenated POE hydrogenated castor oils such as castor oil 60; POE alkyl ethers such as POE (9) lauryl ether POE(20)POP(4) cetyl ether and other POE-POP alkyl ethers; POE(10) nonyl phenyl Examples of the POE alkyl phenyl ethers include POE alkyl phenyl ethers such as phenyl ether. In the compounds shown, POE stands for polyoxyethylene, POP stands for polyoxypropylene, and the The numbers in the parentheses indicate the number of moles added. In addition, the amphoteric surfactants that can be blended in the aqueous composition of the present invention are Specific examples of the alkyldiaminoethylglycine include alkyldiaminoethylglycine. Specific examples of cationic surfactants that can be incorporated into the composition include benzalkonium chloride. Examples of anions that can be blended in the aqueous composition of the present invention include benzotriazole, benzethonium chloride, and the like. Specific examples of the surfactant include alkylbenzene sulfonate and alkyl sulfate. , polyoxyethylene alkyl sulfate, aliphatic α-sulfomethyl ester, α-olefin In the aqueous composition of the present invention, these surfactants are They may be used alone or in combination of two or more.
[0038] Among the above surfactants, the thermal stability of the above component (A) is destabilized by the above component (B). From the viewpoint of further improving the above, a nonionic surfactant is preferable; and more preferably POE sorbitan fatty acid esters, POE hydrogenated castor oils, POE-POP block copolymers; Particularly preferred are polysorbate 80, polyoxyethylene hydrogenated castor oil 60, and POE-POP block. Lycopolymers; particularly preferably polysorbate 80, polyoxyethylene hydrogenated castor oil 60; Most preferably, polysorbate 80 is used.
[0039] When a surfactant is blended in the aqueous composition of the present invention, the blending ratio of the surfactant is as follows: The amount of the surfactant may be appropriately determined depending on the type of the surfactant, the types and amounts of other ingredients, and the intended use of the aqueous composition. As an example of the blending ratio of the surfactant, the surfactant can be set to 1:100:1 with respect to the total amount of the aqueous composition. The total amount of the agent is 0.001 to 1.0 w / v%, preferably 0.005 to 0.5 w / v%, and more preferably Or, for example, 0.01 to 0.3 w / v %.
[0040] The aqueous composition of the present invention preferably further contains a polyhydric alcohol. The polyhydric alcohol used in the present invention is a compound having two or more hydroxyl groups, and is medicinally and pharmacologically effective. There are no particular limitations as long as it is clinically (pharmaceutical) or physiologically acceptable. Specific examples of glycols include glycerin, 1,3-butylene glycol, ethylene glycol, Polyethylene glycol, propylene glycol, sucrose, glucose, lactose, sorbitol , xylitol, mannitol, maltitol, polydextrose and dextrin In the aqueous composition of the present invention, these polyhydric alcohols are They may be used alone or in combination of two or more.
[0041] Among the above polyhydric alcohols, the thermal stabilization of the above component (A) which is destabilized by the above component (B) is preferred. From the viewpoint of further improving the quality, propylene glycol and / or glycol are preferable. Examples include lycerin, and most preferred is glycerin.
[0042] When a polyhydric alcohol is blended in the aqueous composition of the present invention, the blending ratio of the polyhydric alcohol is Regarding the type of polyhydric alcohol, the types and amounts of other blended ingredients, the use of the aqueous composition, etc. The blending ratio of the polyhydric alcohol can be set appropriately according to the total amount of the aqueous composition. The total amount of the polyhydric alcohol is 0.05 to 3.5 w / v%, preferably 0.1 to 3 w / v%. More preferably, the concentration is 0.5 to 2.5 w / v %.
[0043] The aqueous composition of the present invention may further contain an isotonicity agent. The tonicity adjusting agent that can be added is a medicament, pharmacologically (pharmaceutical) or physiologically acceptable agent. As long as it satisfies the above requirements, there is no particular limitation. Specific examples of such isotonicity agents include dihydrogen phosphate Sodium, Sodium Dihydrogen Phosphate, Potassium Dihydrogen Phosphate, Sodium Bisulfite, Sodium sulfite, potassium chloride, calcium chloride, sodium chloride, magnesium chloride , potassium acetate, sodium acetate, sodium bicarbonate, sodium carbonate, sodium thiosulfate Among these isotonicity agents, potassium chloride, magnesium sulfate, etc. Calcium chloride, sodium chloride, magnesium chloride are preferred. These tonicity agents may be used alone or in any combination of two or more.
[0044] When an isotonicity agent is added to the aqueous composition of the present invention, the mixing ratio of the isotonicity agent is determined by the following formula: It is not possible to uniformly prescribe the amount of isotonicity depending on the type of isotonicity agent used. The total amount of the isotonic agent is 0.01 to 10 w / v%, preferably 0.05 to 5 w / v%, and more preferably An example of the ratio is 0.1 to 2 w / v%.
[0045] The aqueous composition of the present invention preferably further contains a buffer. The buffering agent that can be added is a buffering agent that is medicamentally, pharmacologically (pharmaceutical) or physiologically acceptable. As long as it satisfies the above requirements, there is no particular limitation. Examples of such buffers include boric acid buffers and phosphate buffers. agents, carbonate buffers, citrate buffers, acetate buffers, epsilon-aminocaproic acid, aspartate These buffers may be used in combination. Preferred buffers are borate buffers, phosphate buffers, carbonate buffers, and citrate buffers. Boric acid buffers include boric acid, alkali metal borates, and alkaline earth borates. Examples of the phosphate buffer include phosphoric acid, alkali metal phosphate, and the like. Examples of the carbonate buffer include carbonate, Examples of carbonates include alkali metal carbonates and alkaline earth metal carbonates. Examples of the citrate include citric acid, alkali metal citrate, and alkaline earth metal citrate. In addition, borate or phosphate hydrates are used as borate or phosphate buffers. As a more specific example, the boric acid buffer may be boric acid or a salt thereof (sodium borate). Thorium, potassium tetraborate, potassium metaborate, ammonium borate, borax, etc. ); Phosphate buffer, phosphoric acid or its salts (disodium hydrogen phosphate, sodium dihydrogen phosphate) Sodium, potassium dihydrogen phosphate, trisodium phosphate, dipotassium phosphate, monohydrogen phosphate calcium, dihydrogen calcium phosphate, etc.); as a carbonate buffer, carbonic acid or its salts (carbonated water Sodium carbonate, sodium carbonate, ammonium carbonate, potassium carbonate, calcium carbonate, carbon potassium hydrogen carbonate, magnesium carbonate, etc.); citric acid buffer, citric acid or its salts ( Sodium citrate, potassium citrate, calcium citrate, sodium dihydrogen citrate acetic acid buffer, acetic acid or its salts (ammonium acetate, etc.) , potassium acetate, calcium acetate, sodium acetate, etc.); aspartic acid or its salts (A Aspartate, sodium aspartate, magnesium aspartate, potassium aspartate, etc. These buffers may be used alone or in any combination of two or more. They may also be used in combination.
[0046] When a buffer is added to the aqueous composition of the present invention, the blending ratio of the buffer is determined based on the amount of the buffer used. The amount varies depending on the type of buffer, the types and amounts of other ingredients, the intended use of the aqueous composition, etc. However, for example, the total amount of the buffering agent may be 100% based on the total amount of the aqueous composition. 0.01 to 10 w / v%, preferably 0.1 to 5 w / v%, more preferably 0.2 to 2 w / v%, A particularly preferred ratio is, for example, 0.2 to 1 w / v %.
[0047] Among the above buffers, boric acid buffers are particularly preferred. For example, a combination of boric acid and its salts; preferably boric acid and an alkali metal salt of boric acid. and / or alkaline earth metal salts; more preferably boric acid and an alkali metal salt of boric acid. A particularly preferred example is a combination of boric acid and borax. By using such a combination of borate buffers, not only is a buffering effect provided, In addition, the pH of the aqueous composition can be adjusted. As a result, when the aqueous composition is combined with the above-mentioned component (B), When a borate buffer is used, the thermal stability of the component (A) can be further improved. One example of a method for adjusting the pH is to dissolve each component in an aqueous solvent and then adjust the amount of boric acid salt added. This is a method to adjust the pH to the desired level.
[0048] In addition, the thermal instability of component (A) caused by component (B) is generally This is evident when the total amount of borate buffer in the product is 0.2-2 w / v% (especially 0.2-1 w / v%). However, according to the present invention, the borate buffer is contained in the above proportion. This significantly suppresses the thermal destabilization of component (A) caused by component (B), thereby stabilizing the component (A). In view of the effects of the present invention, it is possible to provide an aqueous composition having excellent properties. The preferred proportion of the borate buffer in the aqueous composition of the present invention is: In contrast, the total amount of the borate buffer is 0.2 to 2 w / v%, preferably 0.2 to 1 w / v%. do.
[0049] The aqueous composition of the present invention may further contain a pH adjuster. The pH adjusting agent that can be added is a medicamentarily, pharmacologically (pharmaceutical) or physiologically acceptable agent. There are no particular limitations on the pH adjuster, so long as it is sufficient. Specific examples of such pH adjusters include salts. Acid, aminoethylsulfonic acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, Magnesium hydroxide, triethanolamine, monoethanolamine, diisopropanol Amino acid, sulfuric acid, propionic acid, oxalic acid, gluconic acid, lactic acid, tartaric acid, malic acid, succinic acid Among these pH adjusters, hydrochloric acid, sodium hydroxide, etc. These pH adjusters may be used alone or in combination of two or more. Any combination of the above may be used.
[0050] The aqueous composition of the present invention may be further adjusted, if necessary, to have an osmotic pressure ratio within a range acceptable to the body. The appropriate osmotic pressure ratio varies depending on the application site, dosage form, etc., but is usually 0.7 to 5. The range is preferably 0.0, more preferably 0.9 to 3.0, and particularly preferably 1.0 to 2.0. The osmotic pressure can be adjusted by a method known in the art using inorganic salts, polyhydric alcohols, etc. The osmolality ratio can be measured using 0.9 w / v% sodium chloride based on the 15th revised Japanese Pharmacopoeia. The osmotic pressure is the ratio of the osmotic pressure of the sample to the osmotic pressure of the aqueous solution of 100 g ... The standard solution for measuring the osmolality ratio is sodium chloride (Japanese This Pharmacopoeia standard reagent) is dried at 500-650℃ for 40-50 minutes, then placed in a desiccator (silica gel). Allow to cool in a cool place, weigh out 0.900 g accurately, dissolve in purified water and prepare exactly 100 mL A commercially available standard solution for measuring osmolality ratio (0.9 w / v% sodium chloride aqueous solution) is used.
[0051] The aqueous composition of the present invention may contain, in addition to the above-mentioned components, various pharmacologically active ingredients, so long as they do not impair the effects of the present invention. The composition may contain a combination of functional and biologically active ingredients. There are no particular limitations on the types of such ingredients. For example, antihistamines, decongestants, disinfectants, amino acids, anti-inflammatory agents, astringents, etc. Examples include:
[0052] In addition, the aqueous composition of the present invention may be modified in its use and form as long as the effects of the invention are not impaired. Depending on the condition, various additives are appropriately selected according to the usual method, and one or more types are used in combination. The additives may be contained in an amount of, for example, the following additives: Examples of such ingredients include the various additives listed in the Pharmaceutical Additives Association (ed.). There are no particular limitations, and examples of the additive include carriers, thickeners, preservatives, bactericides or antibacterial agents, chelating agents, and fragrances. Alternatively, a cooling agent and the like can be exemplified.
[0053] As used herein, an aqueous composition refers to a composition that contains water, and typically contains Water is 1% by weight or more, preferably 5% by weight or more, more preferably 20% by weight or more, and further preferably The water contained in the aqueous composition of the present invention is, Any substance may be used as long as it is medicamentously, pharmacologically (pharmaceutical) or physiologically acceptable. For example, Distilled water, tap water, purified water, sterile purified water, water for injection, distilled water for injection, etc. can be used. The definition is based on the 15th Revised Edition of the Japanese Pharmacopoeia.
[0054] The aqueous composition of the present invention contains desired amounts of the above-mentioned components (A), (B), and (C), and optionally Add other ingredients to the desired concentration and adjust the pH to meet the above range. It is prepared by
[0055] The aqueous composition of the present invention can be in various formulation forms depending on the purpose. For example, The aqueous composition of the present invention may be in the form of a liquid, a semi-solid (e.g., ointment, etc.), etc. It is a liquid agent.
[0056] The aqueous composition of the present invention can be used as a preparation of medicines, quasi-drugs, etc., for example. Ophthalmic compositions, nasal compositions, oral compositions, ear drop compositions, subcutaneous compositions, The ophthalmic composition can be used for various purposes such as eye drops, Artificial tears, eyewash, eye ointment, contact lens solution, contact lens care products (contact lenses) Contact lens disinfectant, contact lens preservative, contact lens cleaner, contact The nasal compositions include nasal drops, Oral compositions include oral medications (e.g., liquids, syrups, extracts, etc.) Otoal compositions include ear drops. Subcutaneous The compositions for administration include injections and the like.
[0057] Among the above-mentioned uses, ophthalmic compositions have the advantage that they are easier to distribute than compositions for other uses, such as oral compositions. The concentration of the compound is often very low, so even a slight decrease in content can be a major problem. In particular, eye drops, among ophthalmic compositions, contain only a very small amount of The impact of the decrease in the amount of eyewash and contact lens care products is large. In contrast to the fact that eye drops are often stored under the counter, eye drops are often carried around and therefore can be used during the day. They are often placed on the dashboard of a car or carried around in a bag outdoors. In some cases, the eye drops are exposed to high temperatures, making them highly susceptible to temperature changes. Generally, they are individually packaged in small quantities, and are therefore susceptible to external temperature changes. The aqueous composition of the present invention is thus a formulation that is easily affected by temperature changes. The effect of improving the stability of ophthalmic compositions (especially eye drops) that are susceptible to heat stress under high temperature conditions is also shown. In view of the effects of the present invention, the aqueous composition of the present invention A suitable example is an ophthalmic composition, and a particularly suitable example is an eye drop.
[0058] The aqueous composition of the present invention is provided in any container. The container is not particularly limited, and may be made of glass or plastic, for example. The container for containing the aqueous composition of the present invention may be made of a material that allows the inside of the container to be visually observed. The container may be a transparent container that allows the inside of the container to be seen, or an opaque container that makes it difficult to see inside the container. The term "transparent container" includes both colorless transparent containers and colored transparent containers. Aqueous composition comprising ketotifen and / or a salt thereof and pranoprofen and / or a salt thereof Although it is a material, it is stable even when exposed to heat, and the aqueous composition is unlikely to turn yellow, and there is no change in the appearance properties. This eliminates concerns about the product becoming tarnished, and makes it possible to provide the product in a transparent container. From this viewpoint, a suitable example of a container for containing the aqueous composition of the present invention is a transparent container. It can be done.
[0059] The aqueous composition of the present invention can also exhibit an antiallergic effect based on the above component (A). Furthermore, the aqueous composition of the present invention is also useful as an agent for preventing or alleviating allergic symptoms. Since it also exerts an anti-inflammatory effect based on the above component (B), it is useful for treating or preventing inflammatory diseases. The present invention is also useful as a therapeutic or preventive agent for inflammatory diseases. Examples of inflammatory eye diseases include blepharitis, conjunctivitis, keratitis, scleritis, and episcleritis. inflammation, anterior uveitis, postoperative inflammation, etc.
[0060] 2. Method for improving the heat stability of ketotifen and / or its salt As described above, the heat generated by the coexistence of the component (A) with the component (B) in the aqueous composition The destabilization against the above-mentioned (C) component is blended and the pH of the aqueous composition is adjusted to 6.5 or less. This can be suppressed by
[0061] Therefore, from another aspect, the present invention provides an aqueous composition comprising (A) ketotifen and a salt thereof. (B) at least one selected from the group consisting of pranoprofen and salts thereof (C) dibutylhydroxytoluene is blended with at least one selected from the above, and adjusting the pH of the aqueous composition to 6.5 or less. Also provided is a method for improving the thermal stability of thifen and / or its salts.
[0062] In the method, the types and blending ratios of the components (A) to (C) used, and other components to be blended The types and blending ratios of the aqueous composition, the pH of the aqueous composition, the formulation form and uses of the aqueous composition, etc. are described above. Same as "1. Aqueous composition".
[0063] 3. Agent for improving the thermal stability of ketotifen and / or its salts and its use for As described above, the aqueous composition containing the component (C) and having a pH of 6.5 or less is The instability of the above component (A) caused by the coexistence of the above component (B) with respect to heat is suppressed. can.
[0064] Therefore, from another viewpoint, the present invention provides: (A) a compound selected from the group consisting of ketotifen and its salts; (B) at least one selected from the group consisting of pranoprofen and salts thereof When at least one of the components (A) is present in the aqueous composition, the component (A) is resistant to heat. (C) an agent for improving the stability of the composition, comprising dibutylhydroxytoluene and The aqueous composition is made of an aqueous base adjusted so that the final pH of the aqueous composition is 6.5 or less. The present invention further provides a thermal stability improving agent characterized by the above-mentioned. and (B) pranoprofen and its salts. and at least one selected from the group consisting of (A) and (B), and the component (A) has improved thermal stability. (C) a dibutylhydroxytoluene-containing aqueous composition for producing the aqueous composition comprising the dibutylhydroxytoluene and the aqueous composition The present invention also provides for the use of an aqueous base adjusted so that the final pH of the composition is 6.5 or less. .
[0065] In these inventions, the aqueous composition contains the component (C) and has a final pH of 6.5 or less. The aqueous base adjusted to the above is used as a base for blending components (A) and (B). That is, the aqueous base is the same as that in the aqueous composition described in the above section "1. Aqueous Composition." In the case of a composition containing neither the (A) nor the (B) components, It may contain any ingredient (e.g., various pharmacologically active ingredients, physiologically active ingredients, additives, etc.). In addition, "adjusted so that the final pH of the aqueous composition is 6.5 or less" means the above. By mixing the above aqueous base with component (A), component (B), and optional components as required, This means that the resulting aqueous composition is designed to have a pH of 6.5 or less.
[0066] In these inventions, the types and blending ratios of the components (A) to (C) used, as well as other components blended For information on the types and proportions of ingredients, the pH of the aqueous composition, the formulation form and uses of the aqueous composition, etc., The same as "1. Aqueous composition" above. EXAMPLES
[0067] The present invention will be described in detail below with reference to examples. The present invention is not limited to the above.
[0068] Test Example 1: Thermal Stability Evaluation (1) The test solutions (Test Solutions 1-4) shown in Table 1 below were prepared and the thermal resistance of ketotifen fumarate was examined. Ketotifen fumarate can cause the formulation to turn yellow if it becomes unstable. In this test example, the degree of yellowing of the test solution was examined to determine whether fumaric acid ketone The thermal stability of totifen was evaluated. The specific experimental procedures and results are shown below.
[0069] [Table 1]
[0070] First, the test solutions (test solutions 1-4) shown in Table 1 were prepared. By appropriately adjusting the pH, three types of solutions (specifically, pH 6.2, Immediately after preparation, each test solution was prepared as a solution of pH 7.0 and pH 7.5. After that, each test liquid was placed in a 10 ml glass The solution was filled into vials of 8 ml each, sealed, and stored at 70°C for one week in the dark. After 1 week, the absorbance at 405 nm (A405) of each test solution was measured. The absorbance value of A405 of purified water was also measured at the same time as the control group. The absorbance value of A405 of the blank group was subtracted from the absorbance value of A405 of the test solution. The degree of yellowing was examined.
[0071] The results are shown in Figure 1. As is clear from Figure 1, the plates containing ketotifen fumarate In test solution 1, which does not contain noprofen, no yellowing was observed at pH 6.2. It was confirmed that when the pH was 7.0 or higher, significant yellowing occurred. In test solution 2, which contains pranoprofen together with ketotifen dihydrochloride, However, significant yellowing was observed even with the naked eye, and the degree of yellowing was not considered to be a problem in terms of formulation. It was clear that the pH value was not increased by adding dibutylhydroxytoluene. If the value is 7.0 or more, the yellowing inhibition effect is almost not observed, or conversely, it becomes significantly worse. It was revealed that the pranoprofen was effective in preventing the formation of pranoprofenases (Test Solution 4). In test solution 3, which contains ketotifen but not fumarate, the No yellowing was observed at all.
[0072] On the other hand, surprisingly, in addition to ketotifen fumarate and pranoprofen, dibutyl In test solution 4, which contains hydroxytoluene and has a pH of 6.2, The absorbance value of A405 was significantly decreased, and no yellowing was observed even with the naked eye. As explained above, ketotifen and / or a salt thereof and pranoprofen and / or a salt thereof are used together. It is possible to obtain an aqueous composition that is highly stable against heat and excellent in formulation while maintaining the properties of the composition. It became clear that:
[0073] Test Example 2: Thermal stability evaluation (2) According to Table 2 below, each test solution was prepared and the thermal stability of ketotifen fumarate was evaluated. The specific experimental methods and results are shown below.
[0074] [Table 2]
[0075] First, the test solutions (test solutions 5-7) shown in Table 2 were prepared. By appropriately adjusting the pH, two types of solutions (specifically, pH 6.5 and 7.0). In addition, each test solution in this test example was prepared at 100°C. All were visually confirmed to be colorless and transparent. Then, each test liquid was poured into a 10 ml glass. The solution was filled into glass vials (8 ml each), sealed, and stored at 70°C for one week in the dark. After one week, the absorbance at 405 nm (A405) of each test solution was measured. As a blank group, the absorbance value of A405 of purified water was also measured at the same time. The absorbance value of each test solution was calculated by subtracting the absorbance value of A405 of the blank group from the absorbance value. The degree of yellowing was then examined.
[0076] The results are shown in Figure 2. As is clear from Figure 2, in the same manner as in Test Example 1, In test solution 5, which contains pranoprofen but does not contain pranoprofen, when the pH is 7.0, Significant yellowing occurred. And the product containing pranoprofen along with ketotifen fumarate In test solution 6, significant yellowing was observed at any pH level, which was evident even to the naked eye. In addition, in test solution 7, which further contained dibutylhydroxytoluene, at pH 7.0, In the case of ketotifen fumarate, no inhibition effect against yellowing was observed. In addition to pranoprofen, dibutylhydroxytoluene was added, and the pH was adjusted to In test solution 7, the absorbance value of A405 was extremely low at 6.5, and no yellowing was observed even by visual inspection. I couldn't recognize it properly.
[0077] Test Example 3: Thermal stability evaluation (3) Each test solution shown in Table 3 below was diluted with borax to obtain 2 The solutions were then adjusted to two different pH values (specifically, pH 6.2 and 7.0). The amount of test solution filled into the glass headspace vial was changed from 8 ml to 5 ml. The thermal stability of ketotifen fumarate was evaluated in the same manner as in Test Example 2, except that The evaluation was carried out.
[0078] [Table 3]
[0079] The results are shown in Figure 3. As is clear from Figure 3, the amount of ketotifen fumarate added was 0 Even when the concentration was 0.0345 w / v %, a similar tendency to that in Test Example 1-2 above was observed. That is, at pH 7.0, ketotifen fumarate and pranoprofen were also present. Even when butylhydroxytoluene was added, no yellowing inhibition effect was observed, but at pH 6 When the value is set at .2, the yellowing caused by the coexistence of ketotifen fumarate and pranoprofen is It was found that the change could be suppressed by further combining dibutylhydroxytoluene. It was made.
[0080] Test Example 4: Thermal stability evaluation (4) Each test solution shown in Table 4 below was adjusted to the specified pH by appropriately adjusting the amount of borax. The mixture was then prepared in a glass headspace vial in the same manner as in Test Example 2. The heat stability of ketotifen fumarate in each test solution was evaluated using the method described above.
[0081] [Table 4]
[0082] The results are shown in FIG. 4. As in Test Example 1-3, the results also show that at pH 7.0 In this case, ketotifen fumarate and pranoprofen are used together with dibutyl hydroxypropyl It was confirmed that even when toluene was added, significant yellowing occurred (Test Solution 13). Even in the presence of ketotifen malate and pranoprofen, dibutylhydroxyacetone was When the pH level was adjusted to 6.5 or lower after adding ruthenium, a significant yellowing inhibition effect was observed. It was found that the oxidative stress was suppressed (Test solutions 11 and 12). In the presence of dibutylhydroxytoluene in the mixture and at a pH of 6.5, the non-ionic When polysorbate 80 was used as the surfactant (test solution 12), When hydrogenated castor oil 60 was used (test solution 14), both showed a significant yellowing suppression effect. was recognized.
[0083] In addition, ketotifen fumarate and pranoprofen were mixed with dibutylhydroxytoluene. The mixture was added with polyhydric alcohol (glycerin or propylene glycol) under conditions of pH 6.5. When polyhydric alcohol is included (test solution 12, 16), the same applies when polyhydric alcohol is not included (test solution 1). 5) showed a higher yellowing inhibition effect than the previous study. When the test solution contained ethanol (test solution 12), the yellowing inhibition effect was significantly improved.
[0084] (Overall Consideration) From the above results, it was found that the pH of the aqueous composition after adding dibutylhydroxytoluene was By setting the pH at 6.5 or less, the fumarate ketotoxicity caused by pranoprofen is reduced. The formulation can significantly suppress the thermal instability of the enzyme and does not yellow even under high temperature conditions. It has become clear that an aqueous composition having excellent properties can be obtained. In order to improve the thermal stability of ketotifen diacetate, glyceryl ether is also used as a polyhydric alcohol. Combining phosphorus has also been found to be beneficial.
[0085] Formulation examples Eye drops (Examples 1-12) are prepared according to the formulations shown in Table 5.
[0086] [Table 5]
Claims
[Claim 1] The invention described in the specification.
Citation Information
Patent Citations
Stabilization of pranoprofen and stable aqueous pranoprofen liquid
JP1995304670A
Composition for ophthalmic solution
JP2005272462A
Pranoprofen-containing composition
JP2006232822A
Pranoprofen-containing composition
JP2006232823A
Pranoprofen-containing composition
JP2006249076A
